Summary of case series using biological agents in TAA.

Abbreviations: TCZ (tocilizumab), monoRx (monotherapy), IFX (infliximab), CRP (C-reactive protein), NR (not reported), N/A (not applicable), F/U (followup), RXB (rituximab), ETN (etanercept), ADA (adalimumab).* In these studies, remission was defined using clinical, biochemical and the absence of new radiographic findings.** In these studies, F/U was> 6 mo while patients were in remission.*** Quality Assessment was conducted as follows: Cases series: pts enrolled consecutively or randomly vs hand-picked? Did>90% of the pts enrolled get analyzed? Was a standardized approach used to assess remission (clinical/biochemical/radiographic). Study quality also reflects risk of bias.# These two studies were from the same cohort and the latter was a follow-up of the initial one. The patients were only analysed once, but quality assessments were conducted for both studies.Summary of case series using biological agents in TAA.